Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Human PRAME Antikörper:
anti-Mouse (Murine) PRAME Antikörper:
anti-Rat (Rattus) PRAME Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Polyclonal PRAME Primary Antibody für WB - ABIN540326
Steinbach, Hermann, Viehmann, Zintl, Gruhn: Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. in Cancer genetics and cytogenetics 2002
Cow (Bovine) Polyclonal PRAME Primary Antibody für WB - ABIN2786466
Sakakura, Kubo, Ako, Ikeda, Funayama, Hirahara, Sugawara, Yasu, Kawakami, Momomura: Determinants of in-hospital death and rupture in patients with a Stanford B aortic dissection. in Circulation journal : official journal of the Japanese Circulation Society 2007
Show all 2 Pubmed References
Cow (Bovine) Polyclonal PRAME Primary Antibody für WB - ABIN2786465
Roman-Gomez, Jimenez-Velasco, Agirre, Castillejo, Navarro, Jose-Eneriz, Garate, Cordeu, Cervantes, Prosper, Heiniger, Torres: Epigenetic regulation of PRAME gene in chronic myeloid leukemia. in Leukemia research 2007
Show all 2 Pubmed References
highly enriched in and structurally associated with the matrix of the acrosomal granule in round spermatids, and migrated with the expansion of the AG during acrosomal biogenesis
the expansion of the PRAME family occurred in both autosomes and sex chromosomes
The authors identified PRAME as a promising target antigen for adoptive leukemia therapy.
Knockdown PRAME in HCC cells, increased cell apoptosis was correlated with the proportion of cells in G0/G1 stage, activated p53 mediated apoptosis, and increased cyclin p21 expression.
PRAME is frequently expressed in epithelial ovarian cancer at the mRNA and protein levels, and DNA methylation is a key mechanism regulating its expression.
PRAME is aberrantly hypomethylated and activated in Class 1 and Class 2 uveal melanomas and is associated with increased metastatic risk in both classes
To investigate the impact of gene copy number variation on PRAME expression, plasma cells were sorted from 50 newly diagnosed multiple myeloma patients and 8 healthy volunteers to measure PRAME transcript levels and gene copy numbers by real-time quantitative polymerase chain reaction.
Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells.
Results support the potential utility of NY-ESO-1, PRAME, and MAGEA4 as targets for immunotherapy and as ancillary prognostic parameters in synovial sarcomas.
PRAME plays a role in preventing the invasion and metastasis of lung adenocarcinoma
PRAME is expressed in many primary and metastatic UMs, and about half of the metastatic UMs coexpress PRAME and HLA class I.
PRAME is a downstream factor of SOX17 and LIN28 in regulating pluripotency and suppressing somatic/germ cell differentiation in primordial germ cells, germ cell neoplasia in situ, and seminomas.
In line with its roles in controlling cell growth, RPAME regulates multiple critical cell-growth related genes, including IGF1R oncogene. IGF1R up-regulation contributes to increase of cell growth upon the knockdown of PRAME.
This study demonstrates that PRAME functions as a tumor suppressor in breast cancer.
PRAME is an independent prognostic biomarker in Uveal melanoma , which identifies increased metastatic risk in patients with Class 1 or disomy 3 tumors.
Leukemias expressing high levels of PRAME had higher levels of cell death by regulating S100A4/p53 signaling.
Our results suggest that the leukemias expressing high levels of PRAME has favorable prognosis
PRAME expression is considered as a poor prognostic parameter in HL.
PRAME immunoreactivity in myeloid leukemia (ML) of Down syndrome (DS) is largely due to the non-blast components, while PRAME immunoreactivity in blasts of Transient abnormal myelopoiesis (TAM) is not restricted to cases that progress to ML of DS.
This study shows the prognostic significance of PRAME expression in diffuse large B-cell lymphoma patients treated with R-CHOP therapy.
results suggested that PRAME was a predictor for better outcome, could be a useful target for immunotherapy, and might represent a candidate marker for the monitoring of minimal residual disease
elevated PRAME expression in head and neck squamous cell carcinoma
This gene encodes an antigen that is predominantly expressed in human melanomas and that is recognized by cytolytic T lymphocytes. It is not expressed in normal tissues, except testis. This expression pattern is similar to that of other CT antigens, such as MAGE, BAGE and GAGE. However, unlike these other CT antigens, this gene is also expressed in acute leukemias. Five alternatively spliced transcript variants encoding the same protein have been observed for this gene.
preferentially expressed antigen in melanoma
, Opa-interacting protein OIP4
, cancer/testis antigen 130
, melanoma antigen preferentially expressed in tumors
, opa-interacting protein 4
, preferentially expressed antigen of melanoma